Overview
URGN market data
Price History
URGN price chart · 1M
- O
- 46.04
- H
- 46.33
- L
- 45.36
- C
- 45.63
- Vol
- 23,015.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $46.04
- Previous Close
- $45.91
- Day High
- $46.33
- Day Low
- $45.36
- 52 Week High
- $50.76
- 52 Week Low
- $22.76
- 7 Day Return
- -2.55%
- 30 Day Return
- +11.66%
- 90 Day Return
- +62.25%
- 1 Year Return
- +95.90%
- Daily Notional Volume
- $1.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -51.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.86 – $50.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.4B · P/B 25.38 · P/S 12.87.
Company News
UroGen Pharma shares are trading lower. The company announced a strategic Option and Research License Agreement and a related equity investment agreement with IntraGel Therapeutics.Benzinga · Aug 20, 2026, 5:55 PM
UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel TherapeuticsBenzinga · Aug 20, 2026, 11:25 AM
8-K filing — UroGen Pharma Ltd. (URGN)SEC EDGAR · Aug 20, 2026, 11:04 AM
UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical SolutionBenzinga · Aug 17, 2026, 12:05 PM
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58Benzinga · Aug 6, 2026, 1:48 PM
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75Benzinga · Aug 6, 2026, 10:40 AM
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60Benzinga · Aug 5, 2026, 8:01 PM
UroGen Pharma shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 5, 2026, 1:08 PM
UroGen Pharma Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $72.456M Beat $63.526M EstimateBenzinga · Aug 5, 2026, 12:01 PM
UroGen Pharma shares are trading higher after Guggenheim maintained its Buy rating on the stock and raised its price target from $32 to $42.Benzinga · Jul 21, 2026, 2:46 PM